Viking Therapeutics (VKTX) Insider Trading & Ownership $51.53 +0.02 (+0.04%) (As of 11/20/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Viking Therapeutics (NASDAQ:VKTX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage4.70%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)6Amount OfInsider Selling(Last 12 Months)$81.78 M Get VKTX Insider Trade Alerts Want to know when executives and insiders are buying or selling Viking Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address VKTX Insider Buying and Selling by Quarter Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Viking Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails11/8/2024Lawson MacartneyDirectorSell2,000$68.67$137,340.00 10/28/2024Greg ZanteCFOSell131,687$76.61$10,088,541.07 10/25/2024Sarah Kathryn RouanDirectorSell11,000$80.89$889,790.00 9/20/2024Brian LianCEOSell216,130$70.83$15,308,487.90 9/20/2024J Matthew SingletonDirectorSell10,300$69.50$715,850.00 8/21/2024Brian LianCEOSell1,000$69.90$69,900.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 8/21/2024J Matthew SingletonDirectorSell5,700$69.72$397,404.00 8/19/2024Brian LianCEOSell112,870$65.80$7,426,846.00 8/19/2024J Matthew SingletonDirectorSell16,000$62.22$995,520.00 8/14/2024J Matthew SingletonDirectorSell20,786$57.53$1,195,818.58 7/30/2024Brian LianCEOSell115,859$57.58$6,671,161.22 7/30/2024Marianna ManciniCOOSell18,026$57.13$1,029,825.38 5/3/2024Greg ZanteCFOSell66,756$74.69$4,986,005.64 5/1/2024Marianna ManciniCOOSell281,425$78.66$22,136,890.50 2/8/2024Brian LianCEOSell269,079$26.87$7,230,152.73 2/8/2024Sarah Kathryn RouanDirectorSell25,000$28.05$701,250.00 1/30/2024Brian LianCEOSell35,000$23.95$838,250.00 1/19/2024Sarah Kathryn RouanDirectorSell30,000$23.05$691,500.00 1/4/2024Greg ZanteCFOSell15,000$17.90$268,500.00 (Data available from 1/1/2013 forward) VKTX Insider Trading Activity - Frequently Asked Questions Who is on Viking Therapeutics's Insider Roster? The list of insiders at Viking Therapeutics includes Brian Lian, Charles A Rowland Jr, Greg Zante, J Matthew Singleton, Lawson Macartney, Marianna Mancini, and Sarah Kathryn Rouan. Learn more on insiders at VKTX. What percentage of Viking Therapeutics stock is owned by insiders? 4.70% of Viking Therapeutics stock is owned by insiders. Learn more on VKTX's insider holdings. Which Viking Therapeutics insiders have been selling company stock? The following insiders have sold VKTX shares in the last 24 months: Brian Lian ($45,518,073.55), Charles A Rowland Jr ($1,000,000.00), Greg Zante ($19,290,247.71), J Matthew Singleton ($3,304,592.58), Lawson Macartney ($905,060.00), Marianna Mancini ($24,076,587.88), and Sarah Kathryn Rouan ($2,282,540.00). How much insider selling is happening at Viking Therapeutics? Insiders have sold a total of 2,144,187 Viking Therapeutics shares in the last 24 months for a total of $96,377,101.72 sold. Viking Therapeutics Key ExecutivesDr. Brian Lian Ph.D. (Age 58)President, CEO & Director Compensation: $987.1kMr. Gregory S. Zante (Age 53)Chief Financial Officer Compensation: $655kMs. Marianne Mancini (Age 59)Chief Operating Officer Compensation: $670k1 recent tradesMr. Michael Morneau (Age 59)Vice President of Finance & Administration Compensation: $375.33kDr. Geoffrey E. Barker Ph.D.Senior Vice President of Pharmaceutical Development More Insider Trading Tools from MarketBeat Related Companies PRTA Insider Ownership PBYI Insider Ownership MRNS Insider Ownership TEVA Insider Ownership BGNE Insider Ownership VTRS Insider Ownership SMMT Insider Ownership MRNA Insider Ownership GMAB Insider Ownership PCVX Insider Ownership Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking On This page (NASDAQ:VKTX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viking Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viking Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
